Tags : I-Mab Biopharma

I-Mab Biopharma Expands Collaboration with Wuxi Biologics for three more

Shots: I-Mab plans to license WuxiBody a proprietary platform from Wuxi for the development of three bispecific antibodies with focus on immuno-oncology and auto-immune This colloboration is the expansion of 2017 agreement between the companies which was intended for development and manufacturing of I-Mab pipeline products WuXiBody bispecifics have achieved 16g/L in cell culture titer, […]Read More